What can we learn and what do we need to know amidst the iatrogenic outbreak of exserohilum rostratum meningitis?

Dimitrios P. Kontoyiannis; David S. Perlin; Emmanuel Roilides; Thomas J. Walsh

doi:10.1093/cid/cit283

What can we learn and what do we need to know amidst the iatrogenic outbreak of exserohilum rostratum meningitis?

Dimitrios P. Kontoyiannis
, David S. Perlin
, Emmanuel Roilides
, Thomas J. Walsh

Research output: Contribution to journal › Review article › peer-review

24 Scopus citations

Abstract

The tragedy of the ongoing epidemic of meningitis caused by Exserohilum rostratum brings into focus the epidemiology, risk factors, pathogenesis, diagnosis, and treatment of a multitude of opportunistic mold infections of the central nervous system. Herein we provide our perspective regarding the translational research objectives of this infection that are needed to make an impact on this important healthcare crisis.

Original language	English (US)
Pages (from-to)	853-859
Number of pages	7
Journal	Clinical Infectious Diseases
Volume	57
Issue number	6
DOIs	https://doi.org/10.1093/cid/cit283
State	Published - Sep 15 2013
Externally published	Yes

Keywords

Exserohilum rostratum
antifungals
meningoencephalitis
pathogenesis
risk factors

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/cit283

Cite this

@article{5847f31140b146a0aa6c569128da466d,

title = "What can we learn and what do we need to know amidst the iatrogenic outbreak of exserohilum rostratum meningitis?",

abstract = "The tragedy of the ongoing epidemic of meningitis caused by Exserohilum rostratum brings into focus the epidemiology, risk factors, pathogenesis, diagnosis, and treatment of a multitude of opportunistic mold infections of the central nervous system. Herein we provide our perspective regarding the translational research objectives of this infection that are needed to make an impact on this important healthcare crisis.",

keywords = "Exserohilum rostratum, antifungals, meningoencephalitis, pathogenesis, risk factors",

author = "Kontoyiannis, \{Dimitrios P.\} and Perlin, \{David S.\} and Emmanuel Roilides and Walsh, \{Thomas J.\}",

note = "Funding Information: Potential conflicts of interest. T. J. W. has received research grants for experimental and clinical antimicrobial pharmacotherapeutics from Astel-las, Novartis, Merck, ContraFect, and Pfizer and has served as a consultant to Astellas, ContraFect, Drais, iCo, Novartis, Pfizer, Methylgene, SigmaTau, and Trius. D. P. K. has received research grants from Merck, Pfizer, Astellas, and Gilead and serves on the advisory board of Merck and on the speakers{\textquoteright} bureau of Gilead. D. S. P. has received research support from Astellas, Merck, bioM{\'e}rieux, Myconostica, and Pfizer. E. R. reports no potential conflicts. Funding Information: Financial support. T. J. W. is a Scholar of the Henry Schueler Foundation and a Scholar of Pediatric Infectious Diseases of the Sharpe Family Foundation, and also receives support from the Save Our Sick Kids Foundation (R34HL117352 and 1\$01AI103315-01A1). D. P. K. acknowledges the Frances King Black Endowed Professorship for Cancer Research.",

year = "2013",

month = sep,

day = "15",

doi = "10.1093/cid/cit283",

language = "English (US)",

volume = "57",

pages = "853--859",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",